Scholarlink

Background <p>Acute care encounters for opioid overdose are increasingly recognized as critical opportunities to connect patients to opioid use disorder (OUD) treatment. However, national data on receipt of medication for OUD (MOUD) after overdose events are limited, particularly for new MOUD initiation.</p> Objective <p>To examine MOUD receipt and timing after emergency department or inpatient encounters for opioid overdose, including patient characteristics associated with new MOUD initiation.</p> Design <p>Retrospective analysis of 2014–2019 national Medicaid claims data.</p> Participants <p>Acute care opioid overdose events among non-dual eligible Medicaid enrollees aged 18–64 with continuous enrollment during the 180-day (6-month) baseline period preceding the overdose.</p> Main Measures <p>The primary outcome was any MOUD (buprenorphine, methadone, naltrexone) receipt in the 180&#xa0;days after discharge. Baseline MOUD receipt was categorized by the proportion of days covered (PDC): none (reference), very low (&gt; 0 to &lt; 20%), low (20 to &lt; 50%), moderate (50 to &lt; 80%), high (≥ 80%).</p> Key Results <p>Of 318,536 opioid overdose events, 22.8% and 26.0% had MOUD in the 6 months before and after the event, respectively. Prior MOUD had the strongest association with follow-up MOUD, with a gradient by baseline exposure levels. In Cox models adjusting for patient sociodemographic and clinical covariates, overdose characteristics, and community-level factors, the likelihood of follow-up MOUD was 3.58 times higher for very low (95% CI = 3.50–3.66), 5.47 times higher for low (95% CI = 5.35–5.60), 7.36 times higher for moderate (95% CI = 7.17–7.56), and 16.35 times higher for high (95% CI = 15.92–16.80) baseline MOUD exposure compared to no prior MOUD. Timely follow-up MOUD within 30&#xa0;days was also higher among those with (76.0%) than without (32.4%) prior MOUD.</p> Conclusions <p>Substantial gaps in MOUD receipt after opioid overdose indicate an urgent need to expand acute care interventions for treatment initiation, engagement, and referral as well as broader efforts to increase MOUD prescribing and uptake.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Timely Receipt of New Medication Treatment After Acute Care Encounters for Opioid Overdose in the U.S. Medicaid Population

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月13日

查看全文
  • Hillary Samples,
  • Sharon Cook,
  • Jialiang Hua,
  • Peter Treitler,
  • Elizabeth M. Stone,
  • Jennifer Miles,
  • Mark Olfson,
  • Stephen Crystal

摘要

Background

Acute care encounters for opioid overdose are increasingly recognized as critical opportunities to connect patients to opioid use disorder (OUD) treatment. However, national data on receipt of medication for OUD (MOUD) after overdose events are limited, particularly for new MOUD initiation.

Objective

To examine MOUD receipt and timing after emergency department or inpatient encounters for opioid overdose, including patient characteristics associated with new MOUD initiation.

Design

Retrospective analysis of 2014–2019 national Medicaid claims data.

Participants

Acute care opioid overdose events among non-dual eligible Medicaid enrollees aged 18–64 with continuous enrollment during the 180-day (6-month) baseline period preceding the overdose.

Main Measures

The primary outcome was any MOUD (buprenorphine, methadone, naltrexone) receipt in the 180 days after discharge. Baseline MOUD receipt was categorized by the proportion of days covered (PDC): none (reference), very low (> 0 to < 20%), low (20 to < 50%), moderate (50 to < 80%), high (≥ 80%).

Key Results

Of 318,536 opioid overdose events, 22.8% and 26.0% had MOUD in the 6 months before and after the event, respectively. Prior MOUD had the strongest association with follow-up MOUD, with a gradient by baseline exposure levels. In Cox models adjusting for patient sociodemographic and clinical covariates, overdose characteristics, and community-level factors, the likelihood of follow-up MOUD was 3.58 times higher for very low (95% CI = 3.50–3.66), 5.47 times higher for low (95% CI = 5.35–5.60), 7.36 times higher for moderate (95% CI = 7.17–7.56), and 16.35 times higher for high (95% CI = 15.92–16.80) baseline MOUD exposure compared to no prior MOUD. Timely follow-up MOUD within 30 days was also higher among those with (76.0%) than without (32.4%) prior MOUD.

Conclusions

Substantial gaps in MOUD receipt after opioid overdose indicate an urgent need to expand acute care interventions for treatment initiation, engagement, and referral as well as broader efforts to increase MOUD prescribing and uptake.